Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young

K. Křížková, V. Veverka, L. Maletínská, R. Hexnerová, AM. Brzozowski, J. Jiráček, L. Žáková,

. 2014 ; 9 (11) : e112883. [pub] 20141125

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

The insulin gene mutation c.137G>A (R46Q), which changes an arginine at the B22 position of the mature hormone to glutamine, causes the monogenic diabetes variant maturity-onset diabetes of the young (MODY). In MODY patients, this mutation is heterozygous, and both mutant and wild-type (WT) human insulin are produced simultaneously. However, the patients often depend on administration of exogenous insulin. In this study, we chemically synthesized the MODY mutant [GlnB22]-insulin and characterized its biological and structural properties. The chemical synthesis of this insulin analogue revealed that its folding ability is severely impaired. In vitro and in vivo tests showed that its binding affinity and biological activity are reduced (both approximately 20% that of human insulin). Comparison of the solution structure of [GlnB22]-insulin with the solution structure of native human insulin revealed that the most significant structural effect of the mutation is distortion of the B20-B23 β-turn, leading to liberation of the B chain C-terminus from the protein core. The distortion of the B20-B23 β-turn is caused by the extended conformational freedom of the GlnB22 side chain, which is no longer anchored in a hydrogen bonding network like the native ArgB22. The partially disordered [GlnB22]-insulin structure appears to be one reason for the reduced binding potency of this mutant and may also be responsible for its low folding efficiency in vivo. The altered orientation and flexibility of the B20-B23 β-turn may interfere with the formation of disulfide bonds in proinsulin bearing the R46Q (GlnB22) mutation. This may also have a negative effect on the WT proinsulin simultaneously biosynthesized in β-cells and therefore play a major role in the development of MODY in patients producing [GlnB22]-insulin.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031702
003      
CZ-PrNML
005      
20160826090330.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0112883 $2 doi
035    __
$a (PubMed)25423173
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Křížková, Květoslava $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
245    10
$a Structural and functional study of the GlnB22-insulin mutant responsible for maturity-onset diabetes of the young / $c K. Křížková, V. Veverka, L. Maletínská, R. Hexnerová, AM. Brzozowski, J. Jiráček, L. Žáková,
520    9_
$a The insulin gene mutation c.137G>A (R46Q), which changes an arginine at the B22 position of the mature hormone to glutamine, causes the monogenic diabetes variant maturity-onset diabetes of the young (MODY). In MODY patients, this mutation is heterozygous, and both mutant and wild-type (WT) human insulin are produced simultaneously. However, the patients often depend on administration of exogenous insulin. In this study, we chemically synthesized the MODY mutant [GlnB22]-insulin and characterized its biological and structural properties. The chemical synthesis of this insulin analogue revealed that its folding ability is severely impaired. In vitro and in vivo tests showed that its binding affinity and biological activity are reduced (both approximately 20% that of human insulin). Comparison of the solution structure of [GlnB22]-insulin with the solution structure of native human insulin revealed that the most significant structural effect of the mutation is distortion of the B20-B23 β-turn, leading to liberation of the B chain C-terminus from the protein core. The distortion of the B20-B23 β-turn is caused by the extended conformational freedom of the GlnB22 side chain, which is no longer anchored in a hydrogen bonding network like the native ArgB22. The partially disordered [GlnB22]-insulin structure appears to be one reason for the reduced binding potency of this mutant and may also be responsible for its low folding efficiency in vivo. The altered orientation and flexibility of the B20-B23 β-turn may interfere with the formation of disulfide bonds in proinsulin bearing the R46Q (GlnB22) mutation. This may also have a negative effect on the WT proinsulin simultaneously biosynthesized in β-cells and therefore play a major role in the development of MODY in patients producing [GlnB22]-insulin.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a kultivované buňky $7 D002478
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $x genetika $x metabolismus $7 D003924
650    _2
$a glutamin $x genetika $7 D005973
650    _2
$a lidé $7 D006801
650    _2
$a inzulin $x chemie $x genetika $x metabolismus $x terapeutické užití $7 D007328
650    _2
$a inzulinová rezistence $7 D007333
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a molekulární sekvence - údaje $7 D008969
650    12
$a missense mutace $7 D020125
650    _2
$a vazba proteinů $7 D011485
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Veverka, Václav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Hexnerová, Rozálie $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Brzozowski, Andrzej M $u York Structural Biology Laboratory, Department of Chemistry, The University of York, Heslington, York, YO10 5DD, United Kingdom.
700    1_
$a Jiráček, Jiří $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
700    1_
$a Žáková, Lenka $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic. $7 xx0205795
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e112883
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25423173 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20160826090629 $b ABA008
999    __
$a ok $b bmc $g 1092578 $s 914828
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 11 $d e112883 $e 20141125 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...